AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
âś“. Female patients aged from 18 to 45 years old;
✓. Clinical/trichological evidence of telogen effluvium, assessed using the Telogen Index. 3. Participants will be eligible if they have a rate strand of hair ≥ 20% of the total quantified by Thrichoscan measurement in the central-parietal region;
âś“. Complaint of hair loss for at least 3 months prior to screening;
âś“. Agreement to obey the procedures and requirements of the protocol and to attend the Research Institution on the day (s) and time (s) determined for the evaluations;
âś“. Signature of the Informed Consent Form; SAW. Agreement to use an acceptable non-hormonal contraceptive method throughout the period of treatment and up to 60 days after the end of the study;
âś“. Serum creatinine within the normal range;
✓. Relationship between AST / ALT transaminases ≤ 2.5x the upper limit of normal
Exclusion criteria
âś•. Pregnancy or pregnancy risk;
âś•. Lactation;
âś•. Childbirth occurred in the last 12 months;
âś•. Patient who has undergone surgical procedures or has suffered trauma in the last 6 months;
âś•. History of bleeding events in the last 6 months, SAW. Clinical evidence of female androgenic alopecia or alopecia areata;
What they're measuring
1
Rate difference of anagen hairs at 180 days (FA vf [%]) from baseline rate (FA vi [%]), in participants of each treatment group.